Faeth Therapeutics enters $150M ATM equity facility; Series B preferred converts to common

Sensei Biotherapeutics, Inc.

Entered Sales Agreement with TD Securities for at-the-market offering of common stock up to $150M.
Agent TD Securities receives up to 3% commission; shares sold at market prices from time to time.
Series B Non-Voting Convertible Preferred (24,435.6 shares) automatically converted into 24,435,594 common shares on June 15.
Post-conversion, common shares outstanding increase to 25,778,754 as of June 15, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sensei Biotherapeutics, Inc. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $150,000,000 (effective 2026-06-18).

Action: entry
Agreement: atm program
Counterparty: TD Securities (USA) LLC
Value: up to $150,000,000
Effective: 2026-06-18

Exact text from the filing

On June 18, 2026, Faeth Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC (the “Agent”), pursuant to which the Company from time to time may offer and sell shares (the “ATM Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), through or to the Agent (the “ATM Offering”).

View on SEC.gov

627 material agreements filed in the last 30 days. Browse all material agreements →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-276093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.